KCA banner twitter new
 

Please feel free to forward to fellow researchers and share news of our journal

NEW ISSUE

Dear Colleague,

We are delighted to announce the publication of Volume 5, Issue 4 of our Kidney Cancer journal.

This issue includes a review on sarcomatoid renal cell carcinoma, three research articles, and a systematic review. From the editor of our regular journal section, there is also a new Clinical Trials Corner contribution. View all the open access content via the links below..

***

Call for Papers

As a member of our community, we would like to invite you to submit your own research articles to the journal, which offers contributing authors many benefits:

• First class Editorial Board
• Rigorous peer review and speedy manuscript processing
• Rapid online publication (pre-press) on acceptance
• The first volumes of the journal freely available to all readers
• Articles accepted this year will be published open access with no article processing fee

Submit your manuscript online via Editorial Manager
View detailed Instructions to Authors
Aims and Scope

Kidney Cancer is an international, multidisciplinary journal that provides an invaluable and indispensable platform for the many collaborative, transdisciplinary, and translational efforts to help treat and finally cure this malignancy.

Best wishes,

Primo N. Lara Jr, MD
UC Davis Comprehensive Cancer Center
Sacramento, CA, USA
Email: kca@iospress.com

Peter Mulders, MD, PhD
Radboud UMC
Nijmegen, The Netherlands
Email: kca@iospress.com

Editors-in-Chief


Sign up now for Kidney Cancer news
Join the conversation at: twitter.com/KCA_Journal

KCA newsletter divider

Volume 5, Issue 4 / 2021 Now Available Online

All articles are freely available online for all to read, download and share.

REVIEW ARTICLE
Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms
Candelario, Nellowe | Geiger, Christopher | Flaig, Thomas

RESEARCH ARTICLES
Phase Ib/II trial of Ibrutinib and Nivolumab in Patients with Advanced Refractory Renal Cell Carcinoma
Parikh, Mamta | Tenold, Matthew E. | Qi, Lihong | Lara, Frances | Robles, Daniel | Meyers, Frederick J. | Lara, Primo N.

Retrospective Study of Real-World Treatment Patterns and Outcomes in Advanced/Metastatic Renal Cell Carcinoma Patients Receiving Lenvatinib/Everolimus after Heavy Pretreatment
Vogelzang, Nicholas J. | Monnette, Alisha M. | Wang, Yunfei | Wan, Yin | Robert, Nicholas J. | Tannir, Nizar M.

Prognostic Impact of Lymphnode Metastases in Patients with Metastatic Renal Cell Carcinoma
Eggers, Hendrik | Tiemann, Marie Luise | Peters, Inga | Kuczyk, Markus Antonius | Grünwald, Viktor | Ivanyi, Philipp

SYSTEMATIC REVIEW
First-Line Immuno-Oncology Combinations for Metastatic Clear Cell Renal Cell Carcinoma (mRCC): A Systematic Review of Phase III Clinical Trials
Hahn, Andrew W. | Shah, Amishi Y. | Campbell, Matthew T.

OTHER
Clinical Trials Corner: Reimagining RADICAL
Parikh, Mamta

KCA newsletter divider

Most Viewed Journal Articles in Q4 2021

Listing articles published in 2020 and 2021 so you can read the most popular recent content

First-Line Immunotherapy Combinations in Advanced Renal Cell Carcinoma: A Rapid Review and Meta-Analysis (Systematic Review in Vol.5, Iss.3, 2021)
Shpilsky, Jason | Catalano, Paul J. | McDermott, David F.

Renal Cell Carcinoma with Inferior Vena Cava Extension: Can Classification Be Optimized to Predict Perioperative Outcomes? (Short Communication in Vol.4, Iss.2, 2020)
Leibovich, Bradley C. | Lohse, Christine M. | Cheville, John C. | Potretzke, Theodora A. | Tsivian, Matvey | Shah, Paras H. | Boorjian, Stephen A. | Thompson, R. Houston | Lyon, Timothy D.

Bim Expression in Peritumoral Lymphocytes is Associated with Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma (Research Article in Vol.5, Iss.3, 2021)
Bhindi, Bimal | Bearrick, Elizabeth N. | Cheville, John C. | Lohse, Christine M. | Mason, Ross J. | Shah, Paras | Harrington, Susan | Zhang, Henan | Dong, Haidong | Boorjian, Stephen A. | et al.

First-Line Immuno-Oncology Combinations for Metastatic Clear Cell Renal Cell Carcinoma (mRCC): A Systematic Review of Phase III Clinical Trials (Systematic Review, Vol.5, Iss.4, 2021)
Hahn, Andrew W. | Shah, Amishi Y. | Campbell, Matthew T.

PBRM1 Mutations as a Predictive Biomarker for Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review (Systematic Review in Vol.5, Iss.2, 2021)
Dias Carneiro, André Paternò Castello | Marques Monteiro, Fernando Sabino | Soares, Andrey

Cost-Effectiveness of Immunotherapy Treatments for Renal Cell Carcinoma: A Systematic Review (Systematic Review in Vol.5, Iss.1, 2021)
Philip, Errol J. | Zhang, Sylvia | Tahir, Peggy | Kim, Daniel | Wright, Francis | Bell, Alexander | Borno, Hala T.

KCA newsletter divider

Kidney Cancer Association News

2021 Award Recipients

The Kidney Cancer Association (KCA) has presented two Advanced Discovery Awards, four Young Investigator Awards, and one Focus Award: Psychosocial to researchers who are working to uncover and refine treatment and care strategies for kidney cancer. The awards represent a total of US$1.375 million in funding. “We’re thrilled to support these extraordinary researchers to discover even more about kidney cancer and what can be done to treat it,” said Gretchen E. Vaughan, President and CEO of the Kidney Cancer Association. “Their important work is directly tied to our vision to lead the way to curative therapies for the patients and families in our community.”

This year, a special Focus Award: Psychosocial was introduced in response to the need from both patients and researchers for a better understanding of the psychosocial issues facing people impacted by kidney cancer such as mental and emotional health. This award grants one researcher US$75,000. “Expanding the scope of our award program was really important,” said Sallie McAdoo, MS, CGC, the KCA’s Medical Director. “Addressing the psychosocial needs of people with kidney cancer is a critical part of our mission to provide support and education across the spectrum of kidney cancer. The better we can understand these needs and how to serve them, the better we’ll be able to support more patients and families.”

In addition to the new Focus Award: Psychosocial, the KCA granted two $500,000 Advanced Discovery Awards for collaborative research between established clinicians and basic scientists that will make an immediate impact in kidney cancer and four $75,000 Young Investigator Awards to promising researchers in urology and clinical oncology who are planning to pursue an investigative career in kidney cancer.

KCA newsletter divider

Please Share Kidney Cancer News With Your Colleagues

Help Spread the News!

If you know of any colleagues or fellow researchers who are not yet signed up to receive the newsletter, we invite you to share this mailing with them. Click on the visual or access the sign-up link here.

Kidney Cancer has an active social media presence. If you are not yet interacting with the journal on social media, why not take the time today to follow us on Twitter?

Be part of the discussion!

KCA newsletter divider
***

You are receiving this mailing as you are signed up to receive news from us.
You can unsubscibe or alter your preferences at any time by clicking the links below
.

 
 
Powered by Mad Mimi®A GoDaddy® company